Beam Therapeutics Inc

NASDAQ:BEAM 1:00:00 PM EDT

20.01

+0.13 (+0.65%)

4:51:52 PM EDT: $20.28 +0.27 (+1.35%)

Market Cap (Intraday)	2.01B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$12.77 Million
Adjusted EPS	-$1.11

See more estimates

10-Day MA	$18.39
50-Day MA	$17.76
200-Day MA	$23.06

See more pivots

Beam Therapeutics Inc Stock, NASDAQ:BEAM

238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016

United States of America

Phone: +1.857.327.8775

Number of Employees: 483

http://www.beamtx.com

Description

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.